Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
Authors' conclusion
The clinical and QoL benefits observed with intravenous FCM in patients with iron deficiency following stabilization from an AHF episode are independent of diabetes status.
Study context
- Population
- Patients with iron deficiency stabilized following an acute heart failure (HF) episode in AFFIRM-AHF, stratified by diabetes yes/no at baseline (475 with, 633 without diabetes)
- Participants
- 1,108 patients
- Comparison
- Intravenous ferric carboxymaltose vs placebo, by diabetes status
- Ferric carboxymaltose (FCM), diabetesn = 231
- Placebo, diabetesn = 244reference
- FCM, no diabetesn = 327
- Placebo, no diabetesn = 306reference
Methodological detailspost hoc, subgroup analysis by diabetes status
- Post hoc
- Subgroup analysis by diabetes status
Primary result
As reported in the abstract
Total HF hospitalizations and CV death (annualized event rate/100 patient-years) · Week 52
FCM, diabetes vs Placebo, diabetes
Estimate (95% CI)
Relative risk
0.83(0.58–1.81)
FCM, no diabetes vs Placebo, no diabetes
Estimate (95% CI)
Relative risk
0.77(0.55–1.07)
- Interaction between diabetes status and treatment effect
- P for interaction = 0.76
Secondary outcomes
Secondary endpoints (total cardiovascular (CV) hospitalizations and CV death; CV death; total HF hospitalizations; time to first HF hospitalization or CV death; days lost) · Week 52
- Similar findings were observed for secondary outcomes
Change from baseline in KCCQ-12 overall summary score · Week 24
- Numerically greater with FCM vs placebo at almost all time points in both subgroups; no interaction between diabetes and treatment effect at Week 24
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial. Cardiovasc Diabetol. Published 17 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →